Method for preparation of derivative of pyrido[2,3- d]pyrimidine, or its ss-, rs-isomers, or mixture

专利摘要:
2,4-Diamino- and 2-amino-4-hydroxy- derivatives of N-(4-[2-(pyrido[2,3-d]pyrimidin-6-yl)alkyl]-benzoyl)-L-glutamic acids, and the corresponding 5,6,7,8- tetrahydro compounds are antineoplastic agents.The compounds are prepared by hydrolytic or hydrogenolytic removal of carboxylic acid protecting groups from the correspondingly protected glutamic acid derivatives. A typical embodiment is N-(4-[2-(2-amino-4-hydroxy-5,6,7,8,-tetrahydropyrido[2-3-d]pyrimidin-6 -yl)-ethyl]benzoyl)-L-glutamic acid.
公开号:SU1676449A3
申请号:SU864028461
申请日:1986-11-03
公开日:1991-09-07
发明作者:С.Тейлор Эдвард；Питер Бедсли Джордж；Дж.Харрингтон Питер；Р.Флетчер Стефен
申请人:Дзе Трастиз Оф Принстон Юниверсити (Фирма)；
IPC主号:

专利说明:

Homogeneous solution of 0.1 / 5 g of N-J4- (J2- (2-acetamido-4-hydroxypyrid 2,3-d pyrimidIn-6-yl) diethyl ester) U-ethyl 1 benzoyl 1-1, -glutamic acid in 50 ml of methanol containing 3 ml of 1 aqueous solution of sodium hydroxide, stirred at room temperature for 2 hours. Add 2 ml of acetic acid followed by centrifuging to obtain 0.125 g (86%) of the proposed compound, called 5,10-dideazololic acid , in the form of a microcrystalline colorless solid, t0pLo over 2006S
NMR / TFA-d) Ј, Ppm: 2.3-2.7 (m, 2H); 2, / - 3.0 (m, 2H); 3.25 (c0, 5H); 4.9-5.25 (m, 1H); /, 35 (AB ap., AN, J 9 Hz); 8.50 (s, 1H); 8.90 (s, 1H).
Example 2. (2-amino-4-OXY-5,6, /, 8-tetrahydropyrido-2, 3-d-pyrimidin-6-yl) ethylTbenzoyl | - -L-glutamic acid
Diethyl ester (2-acetamido-4-hydroxy-5,6,7,8-tetrahydropyrido 2,3-cG pyrimidin-6-yl) ethyl benzoyl-β-L-glutamic acid is hydrolyzed in Example 1-e
The proposed compound, termed 5,10-didease-5,6, /, 8-tetrahydrofolic acid0, is obtained. Yield 87%, TopPo over 250 COI
NMR (TFA) Ј, rtG 1.7-3.9 (m, 13H); 5.0-5.25 (mg, 1K); /, 45; 7.85 (AB kvs, 4H, J 9 Hz).
Example 30: N-Ј4- 1- (2-amino-4-OXI-5,6,7,8-tetrahydropyrido- {j2,3-d pyrimidin-6-yl) prop-2-shG {benzoyl - L-glutamic acid
Homogeneous solution of 1 /, 5 mg of diethyl ether (2-acetamido-4-hydroxy-5,6,7,8-tetrahydropyrido-2,3-dJ pyrimidin-6-yl npon-2-miJ benzoyl-2 L-glutamic acid in 2 ml of a methanol solution of sodium hydroxide is allowed to stand at room temperature for 2 hours. Most of the solvent is then distilled off under reduced pressure. The mixture is diluted with water and acidified with acetic acid. The precipitate is collected by filtration, washed with water and dried under reduced pressure. pressure (0.1 mm) for 48 h to obtain 9.7 mg (67%) of the proposed compound named 5,10-dipea a-U-methyl--5,6, /, 8-t etrahydrofolic acid, units over 250 С „
NMR Y, RRS: 0.8 / -0.88 (w „s„, 1Н each); 1-2.8 (m, 11H); 3.13 (m „, 1H); 4.59 (m, 1H); 6.96 (d, 2H, J 9 Hz); /, 34 (d, 2H, J 9 Hz),
Example 4 N-f4- 2- (2-pivaloylamino-4-hydroxy-5,6, /, 8-tetrahydropyrido Ј2,3-dJ diethyl ester pyrimidin-6-yl ethyl benzoyl-L-glutamine acid
A mixture of 0.59 g of N- | 4- (2-pivaloylamino-4-hydroxy-pyridoC2, 3-dJ pyrimidin-6-ylethinyl) diethyl ether - benzoyl} -b-glutamic acid and 1.5 g of 5% palladium on carbon 30 ml of trifluoroacetic acid are hydrogenated at 3.7 at room temperature and 24 hours. The reaction mixture is diluted with methylene chloride and filtered through celite. The solvent is removed under reduced pressure. The residue is redissolved in methylene chloride, extracted with saturated sodium bicarbonate solution and dried over anhydrous sodium sulfate. The solvent is removed under reduced pressure. The residue is chromatographed on silica gel using 4% methanol in methylene chloride o as the eluent.
After evaporation of the eluate, 0.6 g (100%) of N-G4-2- (pivaloylamino-4-hydroxy--5.6, /, 8-tetrahydropyrido 2,3-dj pyrimidin-6-yl) diethyl ether is obtained. -L-glutamic acid in the form of white substance ToPLS 250 ° C (
NMR (CDCl}, 300 MHz) and ppm: 1.22 (t, 3N, J), 2 Hz; 1.29 (s, 9H); 1.3 (t., 3N, J 7.2 Hz); 1.61-3.35 (m, 13H); 4.11 (KO, 2H, J 7.2 Hz) 4.23 (ks, 2H, J 7.2 Hz); 4, 7-4.84 (MO, 1H); 5.15 (broad s, 1H); /, 17 (d, 1H, J 7.5 Hz); 7.23 (d, 2H, J 8.1 Hz); 8.56 (earS, 1H) „
IR (KBG), 3400; 3280; 2980; 1/35; 1630; 1570; 1460; 1390; 1350; 1310; 1200; 1155; 1025; 930; 800 „
Calculated,%: C, 61.73; N /, 07; N 12.
C30H37% ° 7
Found,%: C 44.56; H 3.85; N G /, 3; Br 24.38
Example 5o H- 4-Ј2- (2-amino-4-HYDROXY-5,6,7,8-tetrahydropyrido 2,3-dJ pyrimidin-6-yl) ethyl Pben-shL-α-L-glutamic acid
A solution containing 0.53 g of diethyl ether (2- (2-pivaloylamino-4-hydroxy-5, 6, /, 8-tetragndropirido 2, 3-dJ pyrite-shlin-bn-nl) ethmbezozoyl -1- glutamic acid and 3 ml of 1N solution of sodium hydroxide in 50 ml of methanol, stirred / O h at room temperature. The mixture is acidified with acetic acid. The resulting precipitate is filtered and washed with methanol.
After drying under reduced pressure, 0.2 g (50%) of N-J4- 2- (2-amino-4-hydroxy-5,6,7,8-tetrahydropyrido 2, 3-1 pyrimidine-6-yl) are obtained. ) ethyl 1-benzoyl -1, -glutamic acid with the specified properties,
Example 6 A mixture of 1 g of N- | 4- (2- (2-acetamido-4-α-hydroxy-5,6, /, 8-tetrahydropyrido 2, 3-s-pyrimidin-6-yl) ethyl-benzoyl ( -L-glutamic acid and H80 mg d (+) - Yu-camphor sulfonic acid in 50 ml of anhydrous ethanol is boiled for 4 hours. The reaction mixture is cooled to room temperature and left overnight. The white substance is separated by filtration,
A sixfold fractional crystallization from ethanol gives 3 / mg of diastereomer B d (+) 10-klmorsulfonate of diethyl ether M- {4-7- (2-acetames to-4-hydroxy-5, 6, /, 8-tetrahydropyrido G2, 3 irimidin-6-yl) -ethyl-benzoyl-L-glutamic acid, t „pl0 223-225 ° C,
№ „Ј
The solvent is removed from the mother liquor by evaporation. The solid obtained is recrystallized twice from ethanol.
The diastereomer B d (+) - 10-camphorsulfonate of diethyl ether is obtained (2-aethamido-4-hydroxy-5,6,7,8-tetrahydropyrido Ј2,3-djnnpH Midin-6-yl ethyl benzoylT - L-glutamic acid MS , “YES- -29,35 °,
Example 1, Diastereomer B N- | A- 2- (2-aMHHo-4-rHflpoKCH-5,6,7,8- -tetrahydropyrido 2,3-dJnnoHMHflHHH-6-yl) ethylJbenzoyl-L-luttaminoic acid
A solution of diastereomer B d (+) - 10-camphorsulfonate of diethyl ether (2-acetamido-4-hydroxy--5,6,7,8-tetrahydropyrido 2,3-dlnHpH-midin-6-yl) ethyl beneroyl-L-glutamine acids in 50 ml of methanol containing 3 ml of 1N. hydroxide solution
five
peremenipayut / 2 h at room temperature with the formation of the nltrngpy salt of the diastereomer In N-J4-j 2- (2-aMH-but-4-hydroxy-5 6,1,8-tetragyropy-Jrido 2, 3 - (- -6-yl) methylPbepsoylb-L-glutamic acid.
Add 2 ml of acetic acid followed by centrifugation to obtain Q free acid, t, mp 224-22 / ° С (raelo),
MB & Oi -21.0581 ° (c 0.636, 0.1 n "No. UN), 3
Zmak 2/8; 222 nm
NMR (CDC13) (, ppm: 1.85 (m „, 2H); 1.98 (MO, 1H); 2.25 (m ,, 1H); 2.45 (m., PO; 2.68 ( m „, 1H); 2.92 See, 5H); 3.25 (t, 1H, J 10 Hz); 0 3.82 (d„, H, J 10 Hz); 5.13 (m , 1H); 7.43 (d., 2H, J 9 Hz); /, 84 (d, 2H, J 9 Hz) e
Optical purity 9 /% 0 Example 8 Dilstereomer A 5 m- {4- 2- (2-amino-4-hydroxy-5,6,7,8- -tetrahydropyrido L2,3-dJnHpHMHflHH-6-yl) etst benzoyl | -L-grryttaminovoy
ACID
According to the method of example 7, but using the diastereomer A d (+) - 10-camphorsulfonate of diethyl ether N-G4- Ј2- (2-acetamido-4-hydroxy- -5,6, /, 8-tetrahydropyrido 2,3- dJnn-rimidin-6-yl) ethyl benzoyl-L-glutamic acid; instead of diastereomer B, the diastereomer A N- | 4- 2- (2-LIMINO-4-HYDROXY-5,6,7,8-tetrahydropyrido) is obtained 2,3 pyrimidine-6-yl) ethyl benzoyl) -L-glutamic acid,
0 t0shk 253-255 С (raeLoK
(od) | q + 31.0915 ° (c 3.605, 0.1 n, NaOH) AMSKS 2/8; 222 nm
NMR (CDC1,) 8, ppp: 1.85 (m, 2H); 1.98 (mea, 1H); 2.25 (m „, 1H); 2.45
5 (m, 1H); 2.68 (Mo, 1H); 2.92 (m, 5H); 3.25 (t, 1H, J 10 Hz); 3.82 (d .. 1H, J 10 Hz); 5.13 (m. 1H); 7.43 (Up to, 2H, J = 9 Hz); 7.84 (d, 2H, J 9 Hz) o
0 Optical purity 97% „
Example 9. In 40 ml of water (pH about 5) 10 g of N- {4-G2- (2-amino-4-hydroxy-5,6,7,8-tetrahydropyrido 2,3-d J pyrimidine 5 - 6-yl) ethyl 1-benoyl-T-L-glutamic acid (diastereomer B). To the resulting suspension, 8 ml of 5 and aqueous sodium hydroxide solution are added dropwise with stirring.
1N solution of sodium hydroxide in water until the solid has gone into solution (about 3.5 ml), the pH of the resulting solution is about 8 °. Then 50 ml of methanol is added. The solution is left overnight in the refrigerator. The precipitate formed is filtered off, washed with a small amount of cold metal. After drying at room temperature in vacuo, the disodium salt of diastereomer B of M- | 4-Ј2- (2-amino-4-hydroxy-5,6,7,8-tetrahydropyri- )- to 2.3 -cf pyrimzodin-6-yl) ethesubenzoyl-T-b-glutamic acid (8.1 g), IR (KBg), 3440-3120; 1640; 1620; 1600; 1548; 1504; 1402; 1368; 1310 cm 1,
NMR (DZ0, 300 MHz), ppin: 7.76 (d „, 2H, J 6 Hz); 4.32 (k „, 1H, J 9 Hz); 3.33 (k „, 1H, Hz, 2 G 2.95 (q, 1H, J 11.9 Hz); 2.75 (m„, 2H); 2.55 (q, 1H, J 11 Hz, 3 Hz); 1.2 (t, 2H, J 7 Hz); 2.17 (m0, 1H); 2.14 (m, 2H); 1.76 (m „, 1H); 1 , 68 (MC, ЗН) о
Calculated,%: C 46.58; H 5.4; N 12.93.
C2 "HjjNjOjNa 2
Found,%: C 45.98; H 5.2; N 12.4.
Biological tests of the obtained compounds were carried out.
The IR values of L., determined on human leukemia cell lines (CCRF-CEM), for diastereomer A 5.5-configuration and diastereomer BI, 5 configurations are equal to 2, 3.4 μ-U / g respectively 0
In the axillary region of C57BL / G mice, melanoma B-16 cells are subcutaneously implanted. For each test, ten mice are used. Daily, intraperitoneal injection of N-f4-Ј2- (2-amino-4-hydroxy-5,6,7, 8-tetrahydropyrido 2, 3-dJ pyrimndin-6-yl) ethyl benzoyl-L-glutamic acid, diastereomer A and diastereomer B. After ten days, determine the tumor mass of the control animals that received only a diluent and to calculate percent inhibition compare it with the tumor mass of the animals that received the test compound.
The results are shown in the scoreboard 1 o
g 5
0; "
0
five
0
five
five
10 female CZN mice are injected intraperitoneally in the axillary region with 6C3HED cells of the lymphosarcoma 6C3HED. Then, for 8 days, they inject the test compound in 1P emulsifier (0.5 ml). Control animals are subjected to the same treatment, but do not receive the test compound (see table 0 2) o
CZN mice are implanted with mammary gland adenocarcinoma cells, after which the test compound is administered to them, the control animals receive only diluent (see Table 3).
CZN mice are implanted with myelom X5563 plasma cells, after which the test compound is administered intraperitoneally (0.6 ml / day) into the emulsifier daily for 10 days, the control animals receive only a diluent (see table 4)
In conventional models, these tumor cells are implanted subcutaneously in the axillary region of mice. After intraperitoneal management, the length and width of the tumor is measured in animals receiving the test compound and a control tumor (only saline) in order to deduce the percent inhibition (score 5).
Studies have shown that pyrido derivatives | 2,3-pyrimidine, obtained by the proposed method, is effective against various tumors and inhibitory drugs, unlike methotrexate, of the action of the glycinamide ribonucleotide transformylase (CAP-transformedland) in the course of de novo purine biosynthesis. The same salt has this compound.

权利要求:
Claims (1)
[1]
In addition, pyrido-derived (2, 3-d) pyrimidine, obtained according to the proposed method, belongs to the category of low-toxic compounds.
The method of obtaining the pyrido derivative 2, C-d of pyrimidine of the formula
HE
N YYCH2CH HOH2N 1 N
"N
-CONHCHCH7CH9COOH,
1 L l
COOH
or its SS-, RS-isomers, or mixtures of diastereomers, or pharmaceutically acceptable salts with alkali metalOH5
l Y v-CH2CH2 - - CONH R, HN NN
Nyu
where R is lower alkanoyl;
 RS Cf-Cg-alkyl, is subjected to hydrolysis or hydrogenolysis with subsequent cleavage
lamy, characterized in that the compound of the general formula
TGM,
product in the form of SS-, RS-isomers or a mixture of diastereomers, or pharmaceutically acceptable salts with alkali metals
Table 1
Continuously infuse (2 ml / day) with 1% NaHC03 daily for 5 days,
I
20
59
93
Toxic
0.62 1.25 2.50 5.00
Intraperitoneally (0.5 ml / day) in the pulp bath daily for 10 days
5/5 6/6 6/6 0/6
Intraperitoneally (0.5 ml / day) in emulphorus, days 1, 3, 5, 7 and 9
50 100 200 400
Intraperitoneally (0.6 ml / day) in the emulphor, only in 1,3,5,7 and 9 days
Table 3
(2 ml / day for 5
5/5 6/6 6/6 0/6
10/10 10/10 10/10 8/10
T a b l and c a 4
Table 5
Adenocarcinoma of the mammary gland SZN
Lewis lung carcinoma
Ovarian carcinoma
5-day delay; Toxic dose.
Continuation of table.5
100 100
10 10

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU1676449A3|1991-09-07|Method for preparation of derivative of pyrido[2,3- d]pyrimidine, or its ss-, rs-isomers, or mixture of diastereoisomers, or pharmaceutically accessible salts with alkaline metals

---

JP3016876B2|2000-03-06|N- | glutamic acid derivatives

---

US5344932A|1994-09-06|N-|pyrimidin-3-ylacyl)-glutamic acid derivatives

---

US4845216A|1989-07-04|Pyrido [2,3,d]pyrimidine derivatives

---

KR880002707B1|1988-12-26|Preparation process for urea derivatives

---

KR20010014020A|2001-02-26|Barbituric acid derivatives with antimetastatic and antitumor activity

---

AU3819099A|1999-11-08|Heterocyclically substituted amides used as calpain inhibitors

---

JP2003511377A|2003-03-25|Compound

---

Rewcastle et al.1991|Potential antitumor agents. 63. Structure-activity relationships for side-chain analogs of the colon 38 active agent 9-oxo-9H-xanthene-4-acetic acid

---

US4889859A|1989-12-26|Pyrido[2,3-d]pyrimidine derivatives

---

JP2679737B2|1997-11-19|L-glutamic acid derivative

---

IL97249A|1995-01-24|4,5,6,7- Tetrahydrothiazolo | pyridine and 5,6-dihydro-4h pyrrolo | thiazolo compounds, their production and pharmaceutical compositions containing them

---

CA2207429A1|1996-06-20|Polyarylcarbamoylaza - and - carbamoylalkanedioic acids

---

US4927828A|1990-05-22|Diastereoisomeric tetrahydropyrido-| pyrimidine derivatives

---

PT2240482E|2013-09-06|Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals

---

CN103492392B|2015-11-25|Thieno-[2,3-d] pyrimidine derivatives and be used for the treatment of ARR purposes

---

KR950004894B1|1995-05-15|Process for preparing tetrahydropyrido£2,3-3|pyrimidine derivatives

---

US4833145A|1989-05-23|4|-oxo-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine derivatives

---

CA1301156C|1992-05-19|4|-oxo-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine derivatives

---

US4920125A|1990-04-24|L-glutamic acid derivatives

---

DK172753B1|1999-06-28|N- | -glutamic acid derivatives, their use, pharmaceutical preparations

---

EP0681584B1|2001-06-06|Condensed heterocyclic glutamic acid derivatives as antiproliferative agents

---

US5019577A|1991-05-28|Novel compounds and use

---

US3703517A|1972-11-21|4-|amino)-5-pyrimidine-carboxylic acid esters

---

US4906753A|1990-03-06|Preparation of 2,6-disubstituted-5-cyano-4-pyrimidinyloxyacetic acid aldose reductase inhibitors

同族专利:

---

公开号 | 公开日

---

IE63653B1|1995-05-31|

---

JPS62502535A|1987-10-01|

---

AU5510886A|1986-09-24|

---

KR870700067A|1987-02-28|

---

HUT41785A|1987-05-28|

---

EG18371A|1993-04-30|

---

PH23136A|1989-05-11|

---

ES552684A0|1987-03-16|

---

JPH0822860B2|1996-03-06|

---

ES8801268A1|1987-12-16|

---

ES8704167A1|1987-03-16|

---

MX9203357A|1992-07-01|

---

PT82149B|1988-04-21|

---

DE3689250D1|1993-12-09|

---

HU196202B|1988-10-28|

---

CN86101475A|1987-01-21|

---

ZA861235B|1986-10-29|

---

AU578813B2|1988-11-03|

---

CN1016174B|1992-04-08|

---

IE860561L|1986-09-08|

---

IL78059A|1989-06-30|

---

DE3689250T2|1994-03-03|

---

KR940002952B1|1994-04-09|

---

EP0215063B1|1993-11-03|

---

ES557174A0|1987-12-16|

---

DK472186D0|1986-10-02|

---

NZ215404A|1990-03-27|

---

EP0215063A1|1987-03-25|

---

PT82149A|1986-04-01|

---

IL78059D0|1986-07-31|

---

GR860592B|1986-06-26|

---

EP0215063A4|1987-11-23|

---

DK168666B1|1994-05-16|

---

DK472186A|1986-12-19|

---

JPH08193084A|1996-07-30|

---

CA1276637C|1990-11-20|

---

WO1986005181A1|1986-09-12|

---

AT96790T|1993-11-15|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US4512992A|1980-06-13|1985-04-23|Burroughs Wellcome Co.|Treatment with dialkoxy pyridopyrimidine compounds|

---

US4431805A|1981-09-25|1984-02-14|Southern Research Institute|Pyrido[2,3-d]-pyrimidines|

---

US4526964A|1982-01-11|1985-07-02|Southern Research Institute|2,4-Diamino-6-pyrido[2,3-d]pyrimidine|

---

US4536575A|1982-01-11|1985-08-20|Southern Research Institute|2-Amino-4-oxopyrido[2,3-d]pyrimidino|

---

US4532241A|1982-08-26|1985-07-30|Sri International|8,10-Dideazaminopterins|

---

US4460591A|1982-08-26|1984-07-17|Sri International|8,10-Dideazaminopterins|

---

US4432981A|1982-11-05|1984-02-21|Sterling Drug Inc.|2--8-substituted pyrido[2,3-d]pyrimidin-5-ones|

---

GB2160525B|1983-12-27|1987-08-26|Stanford Res Inst Int|8,10-dideazaminopterins|NZ219971A|1986-06-06|1989-08-29|Univ Princeton|Tetrahydropyrido (2,3-d pyrimidine derivatives and pharmaceutical compositions|

---

IE60038B1|1986-06-30|1994-05-18|Univ Princeton|4-oxo-5, 6, 7, 8-tetrahydropyrido-[2, 3-d]pyrimidine derivatives|

---

US4818819A|1986-10-20|1989-04-04|The Trustees Of Princeton University|Process for the preparation of fused pyridine compounds|

---

GB8702758D0|1987-02-06|1987-03-11|Wellcome Found|Treatment of disease|

---

EP0278686A1|1987-02-07|1988-08-17|The Wellcome Foundation Limited|Pyridopyrimidines methods for their preparation and pharmaceutical formulations thereof|

---

EP0305667A3|1987-09-03|1989-10-25|American Cyanamid Company|Improved process for producing 5,10-dideaza--tetrahydrofolic acid|

---

US4895946A|1987-10-26|1990-01-23|The Trustees Of Princeton University|Process for the preparation of fused pyridine compounds|

---

US4889859A|1988-02-05|1989-12-26|The Trustees Of Princeton University|Pyrido[2,3-d]pyrimidine derivatives|

---

DK172753B1|1988-05-25|1999-06-28|Lilly Co Eli|N--glutamic acid derivatives, their use, pharmaceutical preparations|

---

JPH03173890A|1989-09-21|1991-07-29|Takeda Chem Ind Ltd|Pyrrolopyrimidine derivative, its production, use and intermediate|

---

CA2066898A1|1991-04-29|1992-10-30|Chuan Shih|Pharmaceutical compounds|

---

US5196424A|1992-03-24|1993-03-23|Eli Lilly And Company|N-[2-amino-4-substituted[[[2,3-d]pyrimidinyl]-alkyl]benzoyl]-L-glutamic acids|

---

WO1993020075A1|1992-04-01|1993-10-14|The University Of Sydney|8-substituted-n5-deazapterins as antifolates|

---

ZA932731B|1992-04-23|1994-10-19|Lilly Co Eli|Method of treating gar-transformylase-dependent tumors|

---

DE69327312T2|1992-04-29|2000-07-13|Stanford Res Inst Int|DEAZAAMINOPTERINE FOR TREATING INFLAMMATION|

---

RU2127275C1|1993-01-29|1999-03-10|Агурон Фармасьютикалз, Инк.|2-[4-[2-ethyl]benzoyl -amino]- -pentanedioic acid or its lower alkyl ester, a method of inhibition and proliferation of cells and a method of inhibition of an enzyme activity|

---

US5594139A|1993-01-29|1997-01-14|Agouron Pharmaceuticals, Inc.|Processes for preparing antiproliferative garft-inhibiting compounds|

---

CN1053448C|1994-07-28|2000-06-14|阿格罗尼制药公司|Compounds useful as antiproliferative agents and GARFT inhibitors|

---

EP0783507B1|1994-07-28|2003-06-04|Agouron Pharmaceuticals, Inc.|Compounds useful as antiproliferative agents and garft inhibitors|

---

US5831100A|1995-06-07|1998-11-03|Agouron Pharmaceuticals, Inc.|Syntheses of optically pure compounds useful as GARFT inhibitors and their intermediates|

---

WO2000071160A1|1999-05-24|2000-11-30|Sankyo Company, Limited|MEDICINAL COMPOSITIONS CONTAINING ANTI-Fas ANTIBODY|

---

CA2737496A1|2008-09-17|2010-03-25|Endocyte, Inc.|Folate receptor binding conjugates of antifolates|

法律状态:
2007-09-20| REG| Reference to a code of a succession state|Ref country code: RU Ref legal event code: MM4A Effective date: 20050225 |

优先权:

---

申请号 | 申请日 | 专利标题

---

US70962285A| true| 1985-03-08|1985-03-08|

---